Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04035811 · ClinicalTrials.gov registry record

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

A clinical trial of Achondroplasia, sponsored by QED Therapeutics, a BridgeBio company.

Active
Registry status
271
Enrollment target
20
Study locations

NCT04035811 is a study of Achondroplasia that is active but no longer recruiting, run by QED Therapeutics, a BridgeBio company. The registered enrollment target is 271 participants, above the 121-participant average among 9 other Achondroplasia trials with a reported enrollment target (124% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04035811, a study of Achondroplasia, is active but no longer recruiting, sponsored by QED Therapeutics, a BridgeBio company.

ACTIVE NOT RECRUITING
Registry status
271 participants
Enrollment target
20
Study locations

Study Summary

This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments of study participants. No study medication will be administered.

Conditions Studied

Achondroplasia

Study Locations (20)

Other

  • Hospital de Pediatría SAMIC Prof. Dr. Juan P. Garrahan - Buenos Aires
  • Murdoch Children's Research Institute - Parkville
  • Hopital Femme Mere Enfant - Lyon
  • Hopital Necker-Enfants Malades - Paris
  • Hopital des Enfants - Toulouse
  • Otto-von-Guericke-University Magdeburg Medical Fakulty - Magdeburg
  • Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlino - Milan
  • Rare Disease Unit Fondazione Policlinico A Gemelli IRCCS - Rome

Ontario

  • Children's Hospital - London Health Sciences Center - London
  • University of Ottawa - Ottawa

California

  • Benioff Children's Hospital Oakland - Oakland

Colorado

  • Children's Hospital Colorado - Aurora

Delaware

  • Nemours Alfred I. Dupont Hospital for Children - Wilmington

Maryland

  • Johns Hopkins School of Medicine - Baltimore

Missouri

  • University of Missouri - Columbia

Ohio

  • Cincinnati Children's Hospital - Cincinnati

Trial Details

FieldValue
Enrollment Target 271 participants
Start Date 2019-08-12
Est. Completion 2026-06

Sponsor

QED Therapeutics, a BridgeBio company

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04035811

The ClinicalTrials.gov registry entry for NCT04035811 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 121-participant average among 9 other Achondroplasia trials with a reported enrollment target (124% higher). The listed sponsor is QED Therapeutics, a BridgeBio company, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.

NCT04035811 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, Ontario, California.

Frequently Asked Questions

What is clinical trial NCT04035811 about?

NCT04035811 is a clinical study titled "Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)". This is a long-term, multi-center, observational study in children 2.5 to \<17 years with achondroplasia (ACH). The objective is to evaluate growth, ACH-related medical complications, assessments of health-related quality of life, body pain, functional abilities, cognitive functions, and treatments ...

What is the current status of trial NCT04035811?

This trial is currently active not recruiting. The enrollment target is 271 participants. The study started on 2019-08-12. Estimated completion is 2026-06.

What conditions does trial NCT04035811 study?

This clinical trial studies the following conditions: Achondroplasia.

Who is sponsoring clinical trial NCT04035811?

This trial is sponsored by QED Therapeutics, a BridgeBio company, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04035811 being conducted?

This trial has 20 study locations across California, Colorado, Delaware, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Achondroplasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Achondroplasia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.